Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Neoplasms 1Leukemia, B-Cell 1

Interventions

Cyclophosphamide 10ofatumumab 8fludarabine 6Rituximab 5fludarabine phosphate 4Bendamustine Hydrochloride 4venetoclax 3obinutuzumab 3ibrutinib 3acalabrutinib 3Melphalan 3pirtobrutinib 2Whole-Body Irradiation 2Vincristine 2Tacrolimus 2Peripheral Blood Stem Cell Transplantation 2Patient Reported Outcome Measures 2Mycophenolic Acid 2Mesna 2Lenalidomide 2Immunotherapy, Adoptive 2Busulfan 2Bortezomib 2Alemtuzumab 2zanubrutinib 1thymoglobulin 1tenofovir alafenamide 1pomalidomide 1pivalyloxymethyl butyrate 1pegaspargase 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Leukemia, B-Cell × immunotoxin HA22 × Clear all
NCT02227108 2017-04-06

Study in Pediatrics With Relapsed or Refractory Pediatric Acute Lymphoblastic Leukemia (pALL) or Lymphoblastic Lymphoma

MedImmune LLC

Phase 2 Terminated
37 enrolled 24 charts
LymphoidOther hematologic neoplasm

Neoplasms, Leukemia, B-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡